You are here: Home » Companies » Results
Business Standard

Jubilant Life Sciences Q1 profit declines 52%, revenue at Rs Rs 1,893 cr

Consolidated total revenue from the operations of the company stood at Rs 1,892.92 crore for the quarter under consideration. It was Rs 2,181.86 crore for the same period a year ago

Topics
Jubilant Life Sciences | Q1 results | Pharma sector

Press Trust of India  |  New Delhi 

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Shares of Jubilant Life Sciences closed at Rs 829.60 per scrip on the BSE, up 1.33 per cent from its previous close.

Drug firm on Friday reported a 52.42 per cent decline in its consolidated net profit to Rs 88.01 crore for the quarter ended June 30, 2020.

The company had posted a net profit of Rs184.98 crore for the corresponding period of the previous fiscal, said in a filing to BSE.

' Consolidated total revenue from the operations of the company stood at Rs 1,892.92 crore for the quarter under consideration. It was Rs 2,181.86 crore for the same period a year ago, it added.

"During the quarter, we worked diligently towards employees' safety while continuing to serve our global customers by maintaining our operations," Chairman Shyam S Bhartia and Co-Chairman and MD Hari S Bhartia said.

Overall, barring unforeseen circumstances, "we expect strong performance in our Pharma, Life Science Ingredients (LSI) and Drug Discovery and Development Solutions (DDDS) business in the remaining three quarters of FY21" they added.

Pharmaceuticals revenue was at Rs 1,096 crore for the quarter ended June this year as against Rs 1,328 crore in the first quarter of the financial year 2020, the filing said.

LSI revenue was at Rs 737 crore for the quarter under consideration as against Rs 805 crore in the year ago fiscal period, it added.

Drug Discovery & Development Solutions revenue increased to Rs 60 crore, led by growth in Drug Discovery Services business as against Rs 48 crore for the first quarter of the previous fiscal, the filing said.

"Given the strong demand recovery and new business sign-ups, we believe COVID-19 is not likely to have a material impact on our overall performance during the financial year of 2021, provided the pandemic situation does not materially deteriorate going forward," the filing said.

Shares of Jubilant Life Sciences closed at Rs 829.60 per scrip on the BSE, up 1.33 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, September 04 2020. 19:10 IST
RECOMMENDED FOR YOU
.